Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PRNP | P04156 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721616 | 0.89 | DHODH (0.46) | DHODHRXFP1KDM4ETDP1PDE10A | |
| SCHEMBL3103722 | 0.87 | SMN1; SMN2 (0.41) | KDM4EALDH1A1PRNPMAPTLMNA | |
| SCHEMBL3100644 | 0.85 | DHODH (0.43) | DHODHRXFP1KDM4ETDP1PDE10A | |
| SCHEMBL3110055 | 0.80 | PDE10A (0.56) | DHODHRXFP1KDM4ETDP1PDE10A | |
| SCHEMBL1721514 | 0.79 | SMN1; SMN2 (0.43) | RXFP1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3089755 | 0.79 | CYP1A2 (0.38) | DHODHKDM4EPDE10ALMNAMEN1 | |
| SCHEMBL1721217 | 0.78 | ALDH1A1 (0.36) | RXFP1KDM4ETDP1ALDH1A1PRNP | |
| SCHEMBL1721367 | 0.78 | PDE10A (0.37) | DHODHRXFP1KDM4ETDP1PDE10A | |
| SCHEMBL3098818 | 0.78 | ELANE (0.49) | DHODHKDM4EPDE10AALDH1A1GAA | |
| SCHEMBL1721504 | 0.77 | EPHX2 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2406229-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102811-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNJ2 | DHODH 3196/4885RXFP1 3213/4885KDM4E 367/4885 |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNJ2 | DHODH 3196/4885RXFP1 3213/4885KDM4E 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.